SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
José Luís Piñana, Rodrigo Martino, Lourdes Vázquez, Lucía López‐Corral, Ariadna Pérez, Pedro Chorão, Alejandro Avendaño-Pita, María‐Jesús Pascual, Andrés Sánchez‐Salinas, Gabriela Sanz‐Linares, María Teresa Olave, Ignacio Arroyo, Mar Tormo, Lucı́a Villalón, Venancio Conesa-García, Beatriz Gago, María José Terol, Marta Villalba, Valentín García‐Gutiérrez, Almudena Cabero, José‐Ángel Hernández‐Rivas, Elena Ferrer, Irene García‐Cadenas, Anabel Teruel, David Navarro, Ángel Cedillo, Anna Sureda, Carlos Solano, Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC)
Topics & Concepts
MedicineVaccinationHematopoietic stem cell transplantationImmunologyAntibodyBooster doseAntibody titerTransplantationHazard ratioInternal medicineTiterConfidence intervalSARS-CoV-2 and COVID-19 ResearchCAR-T cell therapy researchCOVID-19 Clinical Research Studies